<DOC>
	<DOCNO>NCT02306135</DOCNO>
	<brief_summary>mTOR kinase part mTORC1 complex promote cap-dependent protein translation , part mTORC2 complex activate AKT . Everolimus ( Afinitor ) allosteric inhibitor mTOR suppress mTORC1 activity . Everolimus FDA-approved treatment ER+/HER2- breast cancer ( combination exemestane ) , renal cell carcinoma , subependymal giant cell astrocytoma ( SEGA ) , neuroendocrine tumor pancreatic origin ( PNET ) , currently test ongoing clinical study indication . While everolimus-based therapy elicit anti-cancer effect , cancer ultimately progress exhibit everolimus resistance . This study evaluate genetic mechanism resistance everolimus .</brief_summary>
	<brief_title>Identifying Mechanisms Resistance mTOR Inhibitors Cancer</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Treatment everolimus ( singleagent combination ) malignancy ≥3 month . 2 . A Patients schedule undergo clinically indicated tumor biopsy ( standard care , part another study ) within 5 year follow cancer progression everolimus eligible . B Patients already biopsy procedure perform eligible . Tumors biopsied shortly progression everolimus strongly prefer . 3 . Excess tumor tissue biopsy must available molecular analysis . This include tumor tissue sufficient make ≥5 fivemicron section ; tumor tissue prefer . 4 . Patients currently see DartmouthHitchcock Medical Center must capable willing provide inform write consent study participation . Patients longer see DHMC consent use archive tissue data . 5 . For patient currently see DartmouthHitchcock Medical Center , patient must willing provide extra 1020 mL blood routine , clinically indicate blood draw procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumor</keyword>
	<keyword>Everolimus</keyword>
	<keyword>mTOR</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Rapamycin</keyword>
</DOC>